The Sonia Elijah Podcast · Investigative journalism, forensic style

James Freeman from The Freeman Report interviews me on TNT Radio

·56 min·3 clips

Sonia says the standard was lowered to 50% RNA integrity, allowing half the mRNA species to be fragmented.

1. The Sonia Elijah Podcast episode centers on James Freeman interviewing Sonia Elijah about her investigation into Pfizer-BioNTech and the EMA. 2. James Freeman is the TNT Radio host, and Sonia Elijah is an investigative journalist with a background in economics who says she writes for Trial Site News, The Conservative Woman, Brownstone Institute, and Children's Health Defense Europe. 3. The episode asks what her new report found in leaked EMA emails and Pfizer-BioNTech documents, and why regulators accepted the outcome. 4. Sonia says lockdowns and school closures pushed her into research-heavy writing, starting with anti-lockdown protests and vaccine documents. 5. She says the FDA documents she read were supposed to stay unreleased for about 96 years, and that she was among the early journalists working through them. 6. She describes a prior career in BBC documentary research and advertising copywriting, which she says helped her detect campaign-style messaging during COVID. 7. Sonia says her current investigation focuses on the Pfizer-BioNTech vaccine, leaked EMA emails, and reports from late 2020. 8. She cites a major objection in the EMA material: a drop in RNA integrity in commercial batches compared with clinical batches. 9. She gives the figures as roughly 55 for commercial batches and 78 for clinical batches, then says regulators asked BioNTech to characterize truncated RNA species. 10. Sonia explains that her report focuses on Western blot testing used to look for proteins expressed by the vaccinal mRNA. 11. She says an anonymous scientific expert used image software to quantify bands and found groups of two or three that appeared copied and pasted. 12. She says such duplication would not occur in an authentic Western blot test, and that the documents describe the work as conventional Western blots. 13. Freeman pushes on the manufacturing scale-up question, comparing small clinical quantities with larger commercial production. 14. Sonia says the issue was not matching the clinical batch quality at scale and that the standard was later lowered to 50% RNA integrity. 15. She says that meant up to half of the mRNA species could be fragmented, and the reports discussed safety and efficacy implications of those fragments. 16. Freeman links the discussion to batch-related injury claims and asks about the MHRA, EMA, FDA, and Health Canada. 17. Sonia says the regulators were concerned, but she describes the process as rushed toward a December 2020 deadline and says the EMA, MHRA, FDA, and Health Canada all appeared to wave it through. 18. The interview is conversational and detailed, with Freeman frequently summarizing Sonia's point and checking technical terms in plain language. 19. Listeners interested in Pfizer documents, EMA emails, and vaccine manufacturing. 20. Listeners who want light news talk without technical document analysis.

As heard by us

A methodical interview about how pandemic questions led to a deeper investigation.

James Freeman frames this interview around Sonia Elijah's move from economics and research into pandemic-era investigation, and the conversation settles on process as much as subject.

Read the full review in PlayNext →

Why you'd press play

Follow the trail from school closures to Pfizer, BioNTech, and EU safety questions.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from The Sonia Elijah Podcast